The EHMT2 antibody targets the enzyme Euchromatic Histone Lysine Methyltransferase 2 (EHMT2. also known as G9a), a key regulator of epigenetic modifications. EHMT2 catalyzes the mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2), a modification associated with transcriptional repression and heterochromatin formation. It plays critical roles in gene silencing, X-chromosome inactivation, and maintaining genomic stability through interactions with chromatin-remodeling complexes. Dysregulation of EHMT2 is linked to developmental disorders, cancer progression, and neurological diseases, making it a focus of therapeutic research.
EHMT2 antibodies are essential tools for studying its expression, localization, and function in cellular processes. They are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to investigate EHMT2's role in epigenetic regulation. Researchers also employ these antibodies to explore its involvement in diseases, such as its overexpression in certain cancers (e.g., leukemia, lung cancer) or its impact on neurodevelopmental pathways. Additionally, EHMT2 inhibitors are being evaluated for their potential to reverse aberrant methylation patterns in disease models. The antibody's specificity and validation are crucial for ensuring accurate interpretation of EHMT2-related mechanisms in both basic and clinical research contexts.